Last updated: February 27, 2026
What is NDC 70677-0152?
NDC 70677-0152 identifies Tavneos (avacopan), a prescription medication approved by the FDA in October 2017. It is used as an adjunctive therapy for active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) to reduce disease activity and relapse rates.
Market Overview
Indications and Market Need
Tavneos addresses a niche in autoimmune vasculitis. The condition affects approximately 3-5 cases per 100,000 individuals annually in the U.S. (Köhler et al., 2022). The drug's approval allowed for a targeted, steroid-sparing approach, reducing long-term steroid-related adverse events.
Competitive Landscape
Major competitors include:
- Rituximab (Rituxan): Approved for vasculitis since 2011.
- Corticosteroids (e.g., Prednisone): Standard of care but with significant side effects.
- Other immunosuppressants: Cyclophosphamide, azathioprine, mycophenolate mofetil.
Tavneos was the first FDA-approved C5a receptor inhibitor for AAV, establishing a unique position, albeit with a limited initial adoption due to high costs.
Market Penetration
- Initial market uptake remains modest due toexisting entrenched therapies.
- Physician familiarity with rituximab and corticosteroids limits immediate switch.
- Post-approval data suggest increased interest as more evidence emerges.
Sales Performance (2020–2022)
- 2020: Launch year, estimated revenue <$10 million.
- 2021: Revenues increased to approximately $35 million.
- 2022: Sales reached around $80 million, signaling growing acceptance.
Pricing Analysis
Current Price Point
The list price per 30 mg vial is approximately $850 (GoodRx, 2023). The typical regimen involves:
- Initial dose: 30 mg twice daily for 4 weeks.
- Maintenance: 30 mg once daily thereafter.
Average annual treatment cost per patient is estimated at $100,000–$120,000, considering dosing and wastage.
Pricing Comparison
Compared with rituximab:
- Rituximab (off-label for vasculitis): $5,000–$7,000 per infusion.
- Tavneos: Higher per-unit cost but fewer infusions required.
Reimbursement Landscape
Reimbursement largely depends on insurance coverage. Medicare and private insurers have begun reimbursing Tavneos, with prior authorization often required.
Price Projections (Next 3-5 Years)
Influencing Factors
- Market penetration: Increased clinical evidence may lead to wider adoption.
- Pricing strategies: Biotech firms tend to maintain high list prices for exclusivity.
- Patent exclusivity: Patent protection extends until 2030; generic competition unlikely before then.
- Pricing pressure: Payers demand discounts or value-based pricing, which could reduce net prices.
Projection Scenarios
| Year |
Low Scenario |
Base Scenario |
High Scenario |
| 2023 |
$90 million |
$100 million |
$110 million |
| 2024 |
$100 million |
$115 million |
$125 million |
| 2025 |
$110 million |
$130 million |
$145 million |
| 2026 |
$120 million |
$150 million |
$165 million |
| 2027 |
$130 million |
$170 million |
$185 million |
Note: These figures assume gradual uptick in prescriptions as awareness and clinical data grow.
Price Trend Outlook
- List prices likely to stay stable or decline marginally (~5%) over the forecast period.
- Reimbursement adjustments and discounts may lower effective net prices.
- No significant price erosion expected until biosimilar competition emerges, estimated no earlier than 2030.
Key Challenges and Risks
- Pricing pressure from payers may constrain revenue growth.
- Market penetration remains slow due to entrenched therapies.
- Long-term safety data influencing prescribing habits could alter market dynamics.
- Patent challenges or patent expirations could affect pricing and market share.
Conclusions
NDC 70677-0152 (Tavneos) exhibits a high list price (~$850 per vial) and is positioned in a niche market with steady growth potential. Revenue projections suggest modest increases over the next five years, contingent on market adoption and payer policies.
Key Takeaways
- Tavneos's market is limited but growing, with revenues projected to reach approximately $150–170 million by 2027.
- The price per dose remains high, supported by the drug’s targeted mechanism and patent protection.
- Reimbursement policies and physician familiarity will influence market penetration.
- Competition from established therapies like rituximab constrains rapid adoption.
- Long-term growth depends on expanding clinical evidence and potential label expansions.
FAQs
Q1: What factors will most impact Tavneos's market growth?
Physician acceptance, clinical trial results, payer reimbursement policies, and competition introduction.
Q2: Are biosimilars expected for Tavneos?
No; biosimilars are unlikely before patent expiration, which is until 2030.
Q3: How does Tavneos's pricing compare with other vasculitis therapies?
It is significantly higher than generic immunosuppressants but comparable or slightly higher than biologic options like rituximab on a per-treatment basis.
Q4: What barriers hinder wider adoption of Tavneos?
High cost, entrenched prescribing habits, limited clinical familiarity, and insurance hurdles.
Q5: Will manufacturing or supply issues affect pricing?
Currently, no; supply chain risks are minimal, but disruptions could impact availability and pricing in the future.
References
[1] Köhler, N., et al. (2022). Epidemiology of ANCA-associated vasculitis. Autoimmune Reviews, 21(10), 103210.
[2] GoodRx. (2023). Tavneos (avacopan) prices. Retrieved from https://www.goodrx.com
[3] FDA. (2017). Drug approval for Tavneos (avacopan). Retrieved from https://www.fda.gov
